Drug Profile
PUR 003
Alternative Names: PUR003Latest Information Update: 22 Sep 2015
Price :
$50
*
At a glance
- Originator Pulmatrix
- Class Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Influenza virus infections
Most Recent Events
- 21 May 2012 Pharmacodynamics and tolerability data from a phase I trial in Asthma released by Pulmatrix
- 15 Dec 2010 Pulmatrix receives grant from US Department of Defense for development of inhaled Cationic Airway Modulator (iCALM) products for infections
- 27 Apr 2010 Pulmatrix completes a phase I trial in Healthy volunteers in United Kingdom